Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Trastuzumab deruxtecan is named as an intervention in 60 current clinical trials in our China, USA, UK, India and Ireland registers. 31 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AstraZeneca (23). The most-studied condition is Breast Cancer.

Trastuzumab deruxtecan also has an approved-drug profile on this site (FDA label data): Enhertu (Trastuzumab Deruxtecan) →

Trials by status

Recruiting3152%
Not yet open58%
Active, closed2440%

Trials by phase

Phase 31932%
Phase 21525%
Phase 1/21017%
Phase 1915%
Observational58%
Phase 412%
Not applicable12%

Clinical trials of Trastuzumab deruxtecan

60 trials

Study	Phase	Status	Lead sponsor	Registers
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer NCT05950945 · Breast Cancer	Phase 3	Recruiting	Daiichi Sankyo	Ireland, USA, China
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) NCT06174987 · ClinicalTrials.gov ↗ · Advanced Cancer, Metastatic Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357 · Biliary Tract Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT06731478 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, China
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) NCT06819007 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, India, China
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer NCT06899126 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, India, China
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, China
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer NCT07022483 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Recruiting	Daiichi Sankyo	USA, China
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) NCT07060807 · Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
Organoid-based Functional Precision Therapy for Advanced Breast Cancer NCT06102824 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Advanced Breast Cancer	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients NCT06832202 · ClinicalTrials.gov ↗ · HER2-low Hormone Receptor Positive Breast Cancer	Phase 2	Recruiting	Shanghai Henlius Biotech	China
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma NCT07069712 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	AstraZeneca	UK, USA, China
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer NCT07393425 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer NCT07497386 · ClinicalTrials.gov ↗ · Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer NCT07678957 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer NCT03424005 · Metastatic Breast Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	UK, USA
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies NCT05417594 · ClinicalTrials.gov ↗ · Advanced Solid Malignancies	Phase 1/2	Recruiting	AstraZeneca	UK, USA
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) NCT05824975 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)	Phase 1/2	Recruiting	GI Innovation, Inc.	USA
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread NCT06324357 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 1/2	Recruiting	Boehringer Ingelheim	UK, USA, China
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors NCT06525298 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency	Phase 1/2	Recruiting	Eisbach Bio GmbH	USA
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC NCT04686305 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 1	Recruiting	AstraZeneca	USA, China
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 NCT05614739 · Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms	Phase 1	Recruiting	Eli Lilly and Company	UK, USA, China
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors NCT05765851 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Daiichi Sankyo	USA
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer NCT06331169 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Recruiting	Fudan University	China
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors NCT07015697 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Solid Tumors	Phase 1	Recruiting	Daiichi Sankyo	USA
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) NCT06210776 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer	Observational	Recruiting	Daiichi Sankyo	China
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns NCT06551220 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Observational	Recruiting	Sun Yat-sen University	China
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China NCT06846996 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction	Observational	Recruiting	Daiichi Sankyo	China
DESTINY-PANTUMOUR04 NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer	Observational	Recruiting	AstraZeneca	USA
Trastuzumab Deruxtecan in Advanced Breast Cancer NCT07180264 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Observational	Recruiting	Wenjin Yin	China
Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer NCT06797622 · ClinicalTrials.gov ↗ · Breast Cancer, Metastatic Breast Cancer	Phase 2	Not yet open	Fudan University	China
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer NCT07630103 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer NCT07825753 · ClinicalTrials.gov ↗ · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)	Phase 2	Not yet open	Fudan University	China
CVL006 Combination Therapy in Advanced Solid Tumors NCT07157956 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Not yet open	Convalife (Shanghai) Co., Ltd.	China
A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer NCT07782086 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Not yet open	Shuangyue Liu	China
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients NCT06429761 · ClinicalTrials.gov ↗ · BREAST CANCER	Phase 4	Active, closed	AstraZeneca	India
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] NCT03529110 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] NCT03734029 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer NCT04494425 · ClinicalTrials.gov ↗ · Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) NCT04622319 · HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer	Phase 3	Active, closed	Daiichi Sankyo	Ireland, UK, USA, China
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) NCT04704934 · ClinicalTrials.gov ↗ · Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Active, closed	Daiichi Sankyo	Ireland, UK, China
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer NCT04739761 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	Ireland, UK, USA
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) NCT04784715 · Breast Cancer; HER2-positive; Metastatic	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations NCT05048797 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer NCT05113251 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy NCT03334617 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors NCT04482309 · ClinicalTrials.gov ↗ · Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, India
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations NCT04639219 · ClinicalTrials.gov ↗ · Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast	Phase 2	Active, closed	AstraZeneca	USA
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC NCT05246514 · ClinicalTrials.gov ↗ · HER2-mutant Non-Small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	China
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors NCT06271837 · ClinicalTrials.gov ↗ · Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)	Phase 2	Active, closed	AstraZeneca	China
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer NCT03742102 · ClinicalTrials.gov ↗ · Triple Negative Breast Neoplasms	Phase 1/2	Active, closed	AstraZeneca	UK, USA
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer NCT04538742 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 1/2	Active, closed	AstraZeneca	UK, USA, India
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies NCT04644068 · ClinicalTrials.gov ↗ · Ovarian Cancer, Breast Cancer, Pancreatic Cancer	Phase 1/2	Active, closed	AstraZeneca	UK, USA, China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer NCT04042701 · Breast Cancer, Non-small Cell Lung Carcinoma	Phase 1	Active, closed	Daiichi Sankyo	UK, USA
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer NCT04556773 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 1	Active, closed	AstraZeneca	USA
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer NCT05650879 · ClinicalTrials.gov ↗ · HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation	Phase 1	Active, closed	Enliven Therapeutics	USA
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors NCT06244485 · Advanced Solid Tumor	Phase 1	Active, closed	Daiichi Sankyo	USA, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Trastuzumab deruxtecan

65 conditions

Breast Cancer12Metastatic Breast Cancer6Advanced Solid Tumor5Gastroesophageal Junction Adenocarcinoma3Advanced Breast Cancer3Breast Neoplasms2Gastric Cancer2Endometrial Cancer2HER2-positive Gastric Cancer2Ovarian Cancer2Locally Advanced or Metastatic Non-Small Cell Lung Cancer2Advanced Cancer2

All 65 conditions

Condition (as registered)	Trials
Breast Cancer	12
Metastatic Breast Cancer	6
Advanced Solid Tumor	5
Gastroesophageal Junction Adenocarcinoma	3
Advanced Breast Cancer	3
Breast Neoplasms	2
Gastric Cancer	2
Endometrial Cancer	2
HER2-positive Gastric Cancer	2
Ovarian Cancer	2
Locally Advanced or Metastatic Non-Small Cell Lung Cancer	2
Advanced Cancer	2
Gastric Cancer, Adenocarcinoma	1
Non-small Cell Lung Carcinoma	1
Biliary Tract Cancer	1
Urinary Bladder Neoplasms	1
Neoplasm Metastasis	1
Ureteral Neoplasms	1
Triple Negative Breast Neoplasms	1
Gastroesophageal Junction Cancer	1
Metastatic Gastric Adenocarcinoma	1
Esophageal Adenocarcinoma	1
Non-small Cell Lung Cancer	1
Gastroesophageal Adenocarcinoma	1
Advanced Solid Malignancies	1
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer	1
Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer	1
Breast Cancer; HER2-positive; Metastatic	1
Advanced or Metastatic Breast Cancer	1
Adenocarcinoma (NOS)	1
Anal Cancer	1
Bladder Cancer	1
Cervical Cancer	1
HER2-positive Early Breast Cancer	1
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast	1
Homologous Recombination Deficiency	1
HRR Deficiency	1
Recurrent or Metastatic Solid Tumors	1
Metastatic Solid Tumor	1
Soft Tissue Sarcoma (STS)	1
Platinum-resistant Ovarian Cancer (PROC)	1
Non-Small Cell Lung Cancer	1
BREAST CANCER	1
HER2-negative Breast Cancer	1
HER2-low Hormone Receptor Positive Breast Cancer	1
HER2-mutant Non-Small Cell Lung Cancer	1
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)	1
HER2 + Breast Cancer	1
HER2-positive Breast Cancer	1
HER2-low Breast Cancer	1
Unresectable Locally Recurrent Breast Cancer	1
Unresectable Locally Metastatic Breast Cancer	1
Advanced or Metastatic Pancreatic Adenocarcinoma	1
Advanced or Metastatic Breast Cancer (BC)	1
HER2-positive Gastroesophageal Junction	1
Solid Cancer	1
HER2-Positive Primary Breast Cancer	1
Residual Invasive Breast Cancer	1
Metastatic Cancer	1
Pancreatic Cancer	1
Prostate Cancer	1
HER2 Mutant Non-small Cell Lung Cancer	1
HER2-positive Metastatic Breast Cancer	1
HER2 Gene Mutation	1
HER2 Amplification	1

By country register

Register	Trials	Recruiting
Clinical trials in China	42	23
Clinical trials in USA	40	21
Clinical trials in UK	26	13
Clinical trials in India	11	4
Clinical trials in Ireland	4	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Trastuzumab deruxtecan trials

How many clinical trials are testing Trastuzumab deruxtecan?

60 current trials in our China, USA, UK, India and Ireland registers name Trastuzumab deruxtecan (also registered as DS-8201a) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Trastuzumab deruxtecan trials recruiting patients?

Yes. 31 of the 60 trials are recruiting: 23 with sites in China, 21 with sites in USA, 13 with sites in UK, 4 with sites in India and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Trastuzumab deruxtecan clinical trials?

AstraZeneca (23), Daiichi Sankyo (16), Fudan University (3) and Merck Sharp & Dohme LLC (1), among 21 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Trastuzumab deruxtecan works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trastuzumab deruxtecan works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trastuzumab deruxtecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Trastuzumab deruxtecan clinical trials